This strategic partnership will enable the integration of NGeneBio's advanced diagnostic assays with MGI's high-throughput sequencing technology to accelerate the development and application of cutting-edge sequencing products in the field of precision medicine, improving patient access to precise diagnostics and personalized treatment options.

Under the MOU, NGeneBio's NGS cancer precision diagnosis products will be applied to MGI's sequencing platform DNBSEQ-G99 to provide healthcare professionals access to a powerful and reliable tool for precision diagnosis and personalized treatment. In addition, the two parties will also join forces in various regional clinical trials and collaborations across the APAC region to strengthen the accessibility and commercialization of cost-effective and state-of-the-art NGS solutions through MGI's extensive network of partners and distributors.

"MGI is proud to collaborate with NGeneBio to develop and commercialize the integrated precision diagnostic platform to enhance the accuracy and efficiency of diagnostic tests," said Dr. Roy Tan, General Manager of MGI Asia Pacific. "By joining forces with NGeneBio, MGI aims to be at the forefront of this revolution to provide healthcare professionals with innovative solutions that can significantly improve patient care and contribute to better health outcomes for individuals around the world."

The field of precision medicine is growing rapidly, with NGS technology playing a crucial role in enabling personalized diagnosis and treatment. MGI's DNBSEQ-G99 sequencer is known for its fast speed and high accuracy, making it an ideal platform for NGS-based precision diagnosis. NGeneBio's expertise in NGS-based precision diagnosis assay platforms will complement MGI's advanced sequencing platforms, creating a powerful synergy aimed at advancing precision medicine.

"We are extremely excited to partner with MGI to develop and deliver cutting-edge diagnostics products that have the potential to transform healthcare and improve patient outcomes, said Choi Dae-chul, CEO of NGeneBio. "By leveraging NGeneBio's NGS-based cancer panel and clinical analysis software with MGI's DNBSEQ™ technology, we can offer a comprehensive solution to meet the needs of healthcare providers in the global market."

Overall, the partnership between MGI and NGeneBio represents a significant step towards advancing precision medicine in the region. By combining their expertise and technologies, the two companies aim to make NGS-based precision diagnosis more accessible, cost-effective, and impactful in healthcare settings. Through their joint efforts in clinical trials, commercialization, and business development, MGI and NGeneBio will contribute to the growth of precision medicine and improve patient outcomes across Asia and beyond.